Company Overview and News

 
SPY And The Cost Of Liquidity

2018-04-20 seekingalpha
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is the oldest U.S. ETF. Having launched in 1993, SPY recently celebrated its 25th birthday and it remains the largest ETF. SPY’s $259 billion in assets are more than $100 billion greater than that of its closest rival, the iShares Core S&P 500 ETF (NYSEARCA:IVV), which has $144 billion. A large asset base helps an index fund track its index with precision. SPY also offers tremendous liquidity with nearly $25 billion in daily dollar volume compared to $1.
Upvote Downvote

 
Big U.S. Stocks' Q4 2017 Fundamentals

2018-04-13 seekingalpha
The big US stocks’ latest quarterly results are concerning. Despite a perfect year for stock markets, and boundless optimism from hopes for big tax cuts soon, corporate profits were flat.
Upvote Downvote

 
Big U.S. Stocks' Q4'17 Fundamentals

2018-04-13 seekingalpha
The big US stocks’ latest quarterly results are concerning. Despite a perfect year for stock markets, and boundless optimism from hopes for big tax cuts soon, corporate profits were flat.
Upvote Downvote

 
Q1 ETF Asset Report: Developed Markets Win, High-Yield Loses

2018-03-29 zacks
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
Upvote Downvote

 
As Bonds And Stocks Fall, What's Gone Up?

2018-03-28 seekingalpha
After a sleepy 2017, stock volatility is back in 2018. But, so far this year, long-dated US treasury bonds have failed to provide an offset to sharp stock falls. However, one asset has done well, performing its portfolio hedging task nicely. That's gold. I continue to recommend a meaningful allocation to physical gold (and even more to cash).
Upvote Downvote

1
Inside February ETF Asset Report

2018-03-02 zacks
February 2018 will be remembered for the brake that the Trump Rally hit after a long and smooth journey. Several market watchers persistently warned of overvaluation and investors have showed amazing patience so far. But the U.S. market crashed to start February.
Upvote Downvote

 
The Last ETF To Buy For Your Core Portfolio

2018-02-28 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

 
The Fourth ETF To Buy For Your Core Portfolio

2018-02-23 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

 
The Third ETF To Buy For Your Core Portfolio

2018-02-22 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

 
Will EM & Asia Outperform U.S. ETFs in the Year of Dog?

2018-02-21 zacks
The global market may have undergone occasional selloffs in 2018 – or the year of dog by Chinese practice – but emerging markets and Asian equities are relatively steady. Emerging-market (EM) ETFs logged their biggest weekly gain last week, since 2016.  
Upvote Downvote

2
How to Invest with Confidence

2018-02-21 zacks
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
Upvote Downvote

 
4 Reasons Why You Should Look at Japan ETFs Now

2018-02-20 zacks
Japan has long been enjoying beneficial easy money policies, which have put the economy on a growth path. Japanese markets saw a stellar run in 2017 with equities riding back to heights last seen in 1991 (read: Japan ETFs Will Continue Their Stellar Run in 2018).
Upvote Downvote

 
Landmark Infrastructure Exposes Investors To Long-Term Multi-Industry Tailwinds

2018-02-20 seekingalpha
Landmark's strategy shields them from a lot of volatility, while providing lots of future growth tailwinds.
Upvote Downvote

 
The Second ETF To Buy For Your Core Portfolio

2018-02-17 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

 
Fred Sanford And The Week That Rocked Markets

2018-02-10 seekingalpha
Let it be that not everyone who warns of risks can be grouped together with the "chicken littles" and the "gollums."
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 922908363